Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194336 · ClinicalTrials.gov registry record
Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance
A clinical trial of Biomarkers, Pharmacological, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- 84
- Enrollment target
- 1
- Study location
NCT01194336 is a study of Biomarkers, Pharmacological that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 84 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01194336, a study of Biomarkers, Pharmacological, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Donepezil
- DRUG Galantamine
- DRUG Huperzine A
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194336
The ClinicalTrials.gov registry entry for NCT01194336 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Biomarkers, Pharmacological appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01194336 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01194336 about?
NCT01194336 is a clinical study titled "Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance". The primary objective of this study is to determine whether huperzine A, donepezil, and galantamine impact militarily relevant aspects of neurocognitive performance in humans, compared to placebo.
What is the current status of trial NCT01194336?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2012-02. Estimated completion is 2012-10.
What conditions does trial NCT01194336 study?
This clinical trial studies the following conditions: Biomarkers, Pharmacological.
What interventions are being tested in trial NCT01194336?
The interventions under investigation include: Placebo (OTHER), Donepezil (DRUG), Galantamine (DRUG), Huperzine A (DRUG).
Who is sponsoring clinical trial NCT01194336?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01194336 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.